BPA
FATE icon

Beacon Pointe Advisors’s Fate Therapeutics FATE Stock Holding History

Beacon Pointe Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-9,100
Closed -$226K – 1023
2022
Q2 		$226K Buy
+9,100
New +$251K ﹤0.01% 934
2021
Q1 		– Sell
-3,500
Closed -$318K – 547
2020
Q4 		$318K Buy
+3,500
New +$217K 0.02% 354

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Beacon Pointe Advisors's FATE Position: Q3 2022 in Review

Beacon Pointe Advisors sold out of Fate Therapeutics (FATE) in Q3 2022, closing a stake of 9,100 shares — an estimated $226K sold.

Beacon Pointe Advisors first reported a position in FATE in Q4 2020 and held it in 2 quarters. The position peaked at $318K in Q4 2020. 239 funds tracked by Wall St. Rank hold FATE as of Q3 2022.

  • Beacon Pointe Advisors reported no remaining Fate Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Beacon Pointe Advisors sold 9,100 Fate Therapeutics shares in Q3 2022, an estimated $226K.
  • Beacon Pointe Advisors first reported a position in Fate Therapeutics in Q4 2020 and held it in 2 quarters.
  • Beacon Pointe Advisors's Fate Therapeutics position peaked at $318K in Q4 2020.
  • 239 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2022.

Based on Beacon Pointe Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.